Source comparison
PT-141 Work for MC4R Research: Comparison With Selective Agonists
PT-141 (Bremelanotide) 12–18 ~1:1 (dual MC3R/MC4R) Yes (cyclic structure) Receptor trafficking, CNS pathway mapping, sexual behavior studies Not currently stocked. Specialized neuroendocrine peptide Setmelanotide 0.27 1:20 (MC4R-biased) Limited (requires intra
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- 12–18
- ~1:1 (dual MC3R/MC4R)
- Yes (cyclic structure)
- Receptor trafficking, CNS pathway mapping, sexual behavior studies
- Not currently stocked. Specialized neuroendocrine peptide
- Setmelanotide
- 0.27
- 1:20 (MC4R-biased)
- Limited (requires intranasal or ICV)
- Isolated MC4R signaling, obesity pathway research, POMC deficiency models
- Not currently stocked. Investigational therapeutic peptide
- MTII (Melanotan II)
- 1.1
- Broad (MC1R/MC3R/MC4R/MC5R)
- Yes (linear but lipophilic modifications)
- Non-selective melanocortin system activation, tanning research, erectile function
- Not currently stocked. Cosmetic/sexual function peptide outside core research focus
- α-MSH (endogenous)
- 2.3
- 1:5 (MC4R-favored but not exclusive)
- No (rapid degradation, poor BBB crossing)
- Physiological baseline reference, short-term in vitro assays
- Not stocked. Native hormone, not stable enough for most protocols
- NDP-MSH (synthetic analog)
- 0.21
- 1:8 (MC4R-biased)
- No (requires ICV for CNS access)
- High-affinity MC4R activation, dose-response characterization
- Not stocked. Specialized synthetic analog